Oral 17β-estradiol continuously combined with dydrogesterone lowers serum lipoprotein(a) concentrations in healthy postmenopausal women

Journal of Clinical Endocrinology and Metabolism

Volumn 82, Issue 11, 1997, Pages 3543-3547

  Mijatovic, V ^a   Kenemans, P ^a   Netelenbos, J C ^a   Peters Muller, E R A ^a   Van Kamp, G J ^a   Voetberg, G A ^a   Van De Weijer, P H M ^a   Van Der Mooren, M J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DYDROGESTERONE; ESTRADIOL; LIPOPROTEIN A;

ADULT; ARTICLE; ATHEROSCLEROSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ESTROGEN ACTIVITY; FEMALE; HORMONAL REGULATION; HUMAN; LIPID METABOLISM; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0030698377     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.82.11.4357     Document Type: Article

References (43)

1. Dahlen GH, Guyton JR, Attar M, Farmer JA, Kautz JA, Gotto AM. 1986 Association of levels of lipoprotein(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation. 74:758-765.
2. Hoefler G, Harnoncourt F, Paschke E, Mitrl W, Pfeiffer KH, Kostner GM. 1988 Lipoprotein(a): a risk factor for myocardial infarction. Arteriosclerosis. 8:398-401.
3. Rosengren A, Wilhelmsen L, Eriksson E, Risberg B, Wedel H. 1990 Lipoprotein(a) and coronary heart disease: a prospective case-control study in a general population sample of middle-aged men. Br Med J. 301:1248-1251.
4. Seed M, Hoppichler F, Reaveley D. 1990 Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N Engl J Med. 322:1494-1499.
5. Scanu AM, Lawn RM, Berg K. 1991 Lipoprotein(a) and atherosclerosis. Ann Intern Med. 115:209-218.
6. Maher VMG, Brown BG. 1995 Lipoprotein(a) and coronary heart disease. Curr Opin Lipidol. 6:229-235.
7. Utermann G. 1989 The mysteries of lipoprotein(a). Science. 246:904-910.
8. Scanu AM, Gunther MF. 1990 Lipoprotein(a). J Clin Invest. 85:1709-1715.
9. Rath M, Niendorf A, Reblin T, Dietel M, Krebber HJ, Beisiegel U. 1989 Detection and quantitation of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis. 9:579-592.
10. Smith EB, Cochran S. 1990 Factors influencing the accumulation in fibrous plaques of lipid derived from low density lipoprotein. Preferential immobilization of lipoprotein(a). Atherosclerosis. 84:173-181.
11. Hajjar KA, Gavish D, Breslow JL, Nachman RL. 1989 Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature. 339:303-304.
12. Heinrich J, Sandkamp M, Kokott R, Schulte H, Assman G. 1991 Relationship of lipoprotein(a) to variables of coagulation and fibrinolysis in a healthy population. Clin Chem. 37:1950-1954.
13. Kim CJ, Ryu WS, Kwak JW, Park CT, Ryoo UH. 1996 Changes in Lp(a) lipoprotein and lipid levels after cessation of female sex hormone production and estrogen replacement therapy. Arch Intern Med. 156:500-504.
14. Schumacher M, Weigert S, Wood WG. 1996 Do gonadotropins influence serum lipoprotein(a) concentrations? Observations in children, adolescents and adults. Eur J Clin Chem Clin Biochem. 34:909-914.
15. Gurakar A, Hoeg JH, Kostner G, Papadopoulos NM, Brewer HB. 1985 Levels of Lp(a) decline with neomycin and niacin treatment. Atherosclerosis. 57:293-301.
16. Berglund L. 1995 Diet and drug therapy for lipoprotein(a). Curr Opin Lipidol. 6:48-56.
17. Van der Mooren MJ, Demacker PNM, Thomas CMG, Borm GF, Rolland R. 1993 A 2-year study on the beneficial effects of 17β-oestradiol-dydrogesterone therapy on serum lipoproteins and Lp(a) in postmenopausal women: no additional unfavourable effects of dydrogesterone. Eur J Obstet Gynaecol Reprod Biol. 52:117-123.
18. Soma MR, Osnago-Gadda I, Paoletti R, et al. 1993 The lowering of lipoprotein (a) induced by estrogen plus progesterone replacement therapy in postmenopausal women. Arch Intern Med. 153:1462-1468.
19. Taskinen MR, Puolakka J, Pyorala T, et al. 1996 Hormone replacement therapy lowers plasma Lp(a) concentrations. Comparison of cyclic transdermal and continuous estrogen-progestin regimens. Arterioscler Thromb Vasc Biol. 16:1215-1221.
20. Mendoza S, Velazques E, Osona A, Hamer T, Glueck CJ. 1994 Postmenopausal cyclic estrogen-progestin therapy lowers lipoprotein(a). J Lab Clin Med. 123:837-841.
21. Haines C, Chung T, Chang A, Masarei J, Tomlinson B. 1996 Effect of oral estradiol on Lp(a) and other lipoproteins in postmenopausal women. A randomised, double-blind, placebo-controlled, crossover study. Arch Intern Med. 156:866-872.
22. Pines A, Mijatovic V, Van der Mooren MJ, Kenemans P. 1997 Hormone replacement therapy and cardioprotection: basic concepts and clinical considerations. Eur J Obstet Gynecol Reprod Biol. 71:193-197.
23. Luciano AA, Turksoy RN, Carleo J, Hendrix JW. 1988 Clinical and metabolic responses of menopausal women to sequential versus continuous estrogen and progestin replacement therapy. Obstet Gynecol. 71:39-43.
24. Rijpkema AHM, Van der Sanden AA, Ruijs AHC. 1990 Effects of postmenopausal oestrogen-progestogen replacement therapy on serum lipids and lipoproteins: a review. Maturitas. 12:259-285.
25. Voetberg GA, Netelenbos JC, Kenemans P, Peters-Muller ERA, van de Weijer PHM. 1994 Estrogen replacement therapy continuously combined with four different dosages of dydrogesterone: effect on calcium and lipid metabolism. J Clin Endocrinol Metab. 79:1465-1469.
26. Thomas CMG, Van den Berg RJ, Segers MFG, Bartelink ML, Thien T. 1993 Inaccurate measurements of 17β-oestradiol in serum of female volunteers after oral administration of milligram amounts of micronised 17β-oestradiol. Clin Chem. 39:2341-2342.
27. Rader DJ, Brewer HB. 1992 Lipoprotein(a), clinical approach to a unique atherogenic lipoprotein. JAMA. 267:1109-1112.
28. Schreiner PJ, Morrisett JD, Sharrett AR, et al. 1993 Lipoprotein(a) as a risk factor for preclinical atherosclerosis. Arterioscler Thromb. 13:826-833.
29. Scanu AM, Fless GM. 1991 Lipoprotein(a): heterogeneity and biological relevance. J Clin Invest. 85:1709-1715.
30. Marsh MS, Crook D, Whitcroft SIJ, Worthington M, Whitehead MI, Stevenson JC. 1994 Effect of continuous combined estrogen and desogestrel hormone replacement therapy on serum lipids and lipoproteins. Obstet Gynecol. 83:19-23.
31. Kim CJ, Jang HC, Cho DH, Min YK. 1994 Effect of hormone replacement therapy on lipoprotein(a) and lipids in postmenopausal women. Arterioscler Thromb. 14:275-281.
32. Soma MR, Meschia M, Bruschi F, et al. 1994 Hormonal agents used in lowering lipoprotein(a). Chem Phys Lipids. 67/68:345-350.
33. Farish E, Rolton HA, Barnes JF, Hart DM. 1991 Lipoprotein(a) concentrations in postmenopausal women taking norethisterone. Br Med J. 303:694.
34. Rymer J, Crook D, Sidhu M, Chapman M, Stevenson JC. 1993 Effects of tibolone on serum concentrations of lipoprotein(a) in postmenopausal women. Acta Endocrinol (Copenh). 128:259-262.
35. Crook D, Sidhu M, Seed M, O'Donnell M, Stevenson JC. 1992 Lipoprotein(a) levels are reduced by danazol, an anabolic steroid. Atherosclerosis. 92:41-47.
36. Gelfland MM, Fugere P, Bissonnette F, et al. 1997 Conjugated estrogens combined with sequential dydrogesterone or medroxyprogesterone acetate in postmenopausal women: effects on lipoproteins, glucose tolerance, endometrial histology, and bleeding. Menopause. 4:10-18.
37. Hearn JA, DeMaio Jr SJ, Roubin GS, Hammarstrom M, Sgoutas D. 1990 Predictive values of lipoprotein(a) and other serum lipoproteins in angiographic diagnosis of coronary artery disease. Am J Cardiol. 66:1176-1180.
38. Snyder ML, Hay RV, Whitington PF, Scanu AM, Fless GM. 1994 Binding and degradation of lipoprotein(a) and LDL by primary cultures of human hepatocytes. Arterioscler Thromb. 14:770-779.
39. Windier E, Kovanen PT, Chao YS, Brown ML, Havel RJ, Goldstein JL. 1980 The estradiol stimulated lipoprotein receptor of rat liver. J Biol Chem. 255:1964-1971.
40. Hofman SL, Eaton DL, Brown MS, McConathy WJ, Goldstein JL, Hammer RE. 1990 Overexpression of human low density lipoprotein receptors leads to accelerated catabolism of Lp(a) lipoprotein in transgenic mice. J Clin Invest. 85:1542-1547.
41. Rader DJ, Cain W, Ikewaki K, Talley G, Zech LA, Usher D, et al. 1994 The inverse association of plasma lipoprotein (a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate. J Clin Invest. 93:2758-2763.
42. McConathy WJ, Trier VN, Koren E, Wang CS, Corder CC. 1994 Triglyceriderich lipoprotein interactions with Lp(a). Chem Phys Lipids. 67/68:105-114.
43. Bass KM, Newschaffer CJ, Klag MJ, Bush TL. 1993 Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med. 153:2209-2216.